A recent prospective observational study of 507 patients with first-ever ischemic stroke showed that treatment with ACE-Is at the time of stroke onset is associated with reduced plasma concentration of C-reactive protein and better long-term outcomes, suggesting that ACE-Is may have antiinflammatory properties and reduce the acute-phase inflammatory response after stroke onset.[21]. The gene discussed is ACE; the disease is ischemic stroke.